Using genetic scores for fasting plasma glucose (FPG GS) and Type 2 diabetes (T2D GS), we investigated whether different diagnostic criteria for gestational diabetes (GDM) have different implications for genetic susceptibility to later T2D in women from the the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies. To investigate different features of WHO (1999) and IADPSG (2010) criteria for diagnosing GDM, cases were divided into three subgroups: (i) FPG ≥ 5.1 mmol/L only, n=261; (ii) 2-hour glucose post 75 g oral glucose load ≥ 7.8 mmol/L only, n=305); and (iii) both FPG ≥ 5.1 mmol/L and 2-hour glucose ≥ 7.8 mmol/L, n=135
Gestational diabetes mellitus (GDM) has been variably defined since criteria were first developed over 50 years ago (1) . The World Health Organization (WHO) introduced diagnostic criteria for GDM in 1999, based on criteria for overt diabetes in the general population with a fasting plasma glucose (FPG) ≥ 7.0 mmol/L or impaired glucose tolerance with a 2-hour glucose post 75 g oral glucose tolerance test (OGTT) ≥ 7.8 mmol/L, measured between 24 and 28 weeks gestation (2) . However, lesser degrees of maternal fasting hyperglycemia have long been associated with a higher risk for adverse perinatal outcomes (3) , so a FPG ≥ 6.1 mmol/L (indicative of impaired fasting glycemia in the non-pregnant population (4)) was also integrated into the WHO criteria.
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study (5) (6) . WHO adopted the recommendations of IADPSG in 2013 (2) , which has resulted in a higher number of cases identified as GDM due to the lower FPG threshold (estimated up to 17 .8% prevalence of GDM for IADPSG 2010 criteria (6) vs 9.4% prevalence for WHO 1999 criteria (7) ). The HAPO Follow-Up Study found that women diagnosed by the newer IADPSG criteria have a higher risk of developing disorders of glucose metabolism, including T2D, 10 years after the episode of GDM (8) . However, for new cases of GDM diagnosed according to the lower FPG threshold, it is not known if there is a genetic predisposition to 4 T2D, or if alternatively, the underlying genetic predisposition is to raised FPG without a genetic predisposition to T2D.
Genome wide association study (GWAS) data from large population-based studies have identified multiple loci associated with FPG (9) and T2D (10) , and various loci associated with fasting hyperglycemia and T2D in the general population have also been associated with GDM (11) (12) (13) . Specific to the IADPSG 2010 criteria, single nucleotide polymorphisms (SNPs) at the GCK and TCF7L2 loci were shown to be associated with FPG and 2-hour glucose levels post-OGTT in women with GDM (14) .
We used a genetic score (GS) for FPG (FPG GS) or T2D (T2D GS) (consisting of previously-identified loci (9, 15) ) to test the hypothesis that there are different genetic risks for fasting hyperglycemia and T2D depending on the criteria used to diagnose GDM.
Research design and methods

Study population
Women of European ancestry with singleton pregnancies and without known pre-existing diabetes from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study (5) (n=2,665) and Atlantic Diabetes in Pregnancy (DIP) study (16) (n=1,119) were included. The HAPO study was an observational, multi-centre study (N=23,316 participants from 15 centres) to which women were recruited during pregnancy if they were over 18 years of age (5) . The 2,665 European-ancestry participants included in the current study were those with genotype data available on selected SNPs (see below). The DIP study had a case-control design: approximately three genotyped control participants without GDM (defined initially as a maternal FPG <5.6 mmol/L and/or 2-hour glucose post oral glucose load <7.8 mmol/L) were available for every genotyped case participant included in our analyses. Women who were unblinded due to being diagnosed with GDM by pre-existing criteria used at the time of the studies were not excluded from this analysis.
Sample collection and clinical characteristics
The study methods used in HAPO and DIP have been described in detail previously (5, 7, (16) (17) (18) . Maternal FPG in mmol/L was measured prior to a standard 2-hour OGTT with 75 g of glucose between 24 and 32 weeks in HAPO and 24 and 28 weeks in DIP. Information on maternal age, pre-pregnancy body mass index (BMI) and systolic blood pressure (SBP, in mmHg) was collected at the OGTT appointment. Clinical characteristics of participants in HAPO and DIP with and without GDM were different (women in DIP were older, had a higher BMI and higher SBP, all P <0.01), hence clinical characteristics have been presented separately.
GDM diagnostic criteria subgroups
We used the IADPSG 2010 and WHO 1999 cut-offs to define fasting and 2-hour hyperglycemia ( Supplemental Table 1 ). Thus, in the current study, women diagnosed with GDM were divided into fasting hyperglycemia only (FPG 
Genotyping
Genotyping of individual SNPs in DNA samples from both the DIP and HAPO studies was carried out at LGC Genomics (Hoddesdon, UK; https://www.lgcgroup.com), using the PCRbased KASP TM genotyping assay. We first selected 41 SNPs that had been previously associated with T2D, and 16 SNPs associated with fasting glucose in non-pregnant individuals, for genotyping in the DIP study. Overlap between the T2D and FPG SNPs meant that 7 FPG loci were also in the list of T2D loci. The median genotyping call rate in the DIP samples was 0.992 (range 0.981-0.996), and there was >99% concordance between duplicate samples (8% of total genotyped samples were duplicates). We excluded one FPG SNP and one T2D SNP that showed deviation from Hardy-Weinberg Equilibrium (Bonferronicorrected P <0.05). For details of included and excluded SNPs and their sources, see Supplemental Table 2 .
In the HAPO study, we selected SNPs from the same 16 FPG and 41 T2D loci for genotyping in women of European ancestry with DNA available. The selection and genotyping of SNPs in the HAPO study was performed at different times from that in the DIP study. Owing to the differing availability of published GWAS results at these times, the genotyped SNPs differed between HAPO and DIP at 9 of the associated loci. The HAPO SNPs at the 9 loci were generally well correlated with those genotyped in DIP (r 2 >0.7, apart from at the ADAMTS9 locus where r 2 = 0.45). The median genotyping call rate in the HAPO samples was 0.984 (range 0.955-0.991), and the mean concordance between duplicate samples was >98.5% (at least 1% of samples were duplicated). We excluded 1 SNP that showed deviation from Hardy-Weinberg Equilibrium in the HAPO study (Bonferronicorrected P <0.05; see Supplemental Table 3 ). After exclusion of SNPs that showed deviation from Hardy-Weinberg equilibrium and one SNP from the T2D score whose main effect was on BMI (rs11642841 (FTO locus) (19) ), a total of 15 SNPs at FPG-associated loci and 38
SNPs at T2D-associated loci were available in both studies for analysis.
Generating a genetic score for FPG and T2D
Weighted genetic scores for FPG (FPG GS) and T2D (T2D GS) were generated using the 15 SNPs and 38 SNPs, respectively. The GSs were calculated by taking the sum of the number of FPG-raising or T2D risk alleles (0, 1 or 2) for each SNP, multiplied by its corresponding beta value (effect size) for association with FPG or T2D, divided by the sum of all beta values and multiplied by the total number of SNPs analyzed (see Supplemental Figure 1 for formula). Where more than 6 SNPs were not called, the individual was excluded from the analysis.
Statistical analyses
Analysis of clinical characteristics
Clinical characteristics were compared between participants with and without GDM in HAPO and DIP using unpaired t-tests for normally distributed data and the Wilcoxon Rank-Sum test for non-normally distributed data. P values were corrected for 18 comparisons using the Bonferroni method.
Analysis of associations between FPG GS or T2D GS with glucose levels and GDM
Associations of the FPG GS or T2D GS with FPG and 2-hour glucose in women with and without GDM (cases and controls) were analyzed using linear regression in HAPO (which was a representative sample of European participants from the whole study cohort). Means for FPG GS and T2D GS in women with and without GDM were compared using unpaired ttests in each study cohort separately, as the genetic scores were higher overall in DIP. P values were corrected for 16 comparisons using the Bonferroni method. We excluded women with a 1-hour glucose value 
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Results
Clinical characteristics in women with and without GDM
Clinical characteristics for women with and without GDM (diagnosed according to fasting hyperglycaemia (FPG mmol/L) per one unit higher FPG GS, P <0.01). FPG was also correlated with the T2D GS, but to a lesser extent (beta coefficient 0.008 mmol/L (95% CI 0.004-0.011 mmol/L) per one unit higher T2D GS, P <0.01). These associations remained present when controlling for the 2-hour glucose values; for FPG the beta coefficient was 0.025 mmol/L (95% CI 0.021-0.030 mmol/L) per one unit higher FPG GS (P <0.01) and 0.005 mmol/L (95% CI 0.001-0.008 mmol/L) per one unit higher T2D GS (P <0.01). The 2-hour glucose values were positively correlated with both FPG GS and T2D GS (beta coefficient 0.032 mmol/L (95% CI 0.016-0.048 mmol/L) per one unit higher FPG GS, P <0.01 and beta coefficient 0.034 mmol/L (95% CI CI 0.022-0.045 mmol/L) per one unit higher T2D GS, P <0.01). The association between 2-hour glucose values and T2D GS remained when taking FPG values into account (beta coefficient 0.027 mmol/L (95% CI 0.016-0.038 mmol/L) per one unit higher T2D GS, P <0.001). However, the association with FPG GS was not present when controlling for FPG (beta coefficient 0.007 mmol/L (95% CI -0.009-0.022 mmol/L) per one unit higher FPG GS, P =0.41).
Women diagnosed with GDM by fasting criteria have a higher FPG GS
We observed a higher FPG GS in women diagnosed with GDM by fasting hyperglycemia only and by both fasting and 2-hour criteria, compared with controls ( Figure 2A ). In HAPO, the mean FPG GS in controls was 15.5 (95% CI 15.4-15.6), whilst in women with a FPG Supplemental Tables 3a and 3b ).
Conclusions
In this study of 3,784 pregnant women of European ancestry, we have shown that women diagnosed with GDM with a FPG ≥ 5.1 mmol/L alone have higher genetic scores for both FPG and T2D. These associations were similar for women who also had a glucose ≥ 7.8 mmol/L at two hours during a standard OGTT, but for women with 2-hour hyperglycemia on its own, there was no genetic predisposition to raised fasting glucose.
We found that FPG in pregnant women both with and without GDM was correlated with a FPG GS which was generated using SNPs identified in a non-pregnant population (11) . The 2-hour glucose values were also correlated with FPG GS, but this could be explained by the association between FPG and 2-hour glucose levels, whereas the association between 2-hour glycaemia and T2D GS was independent of FPG. FPG was correlated with T2D GS, although to a lesser extent than with the FPG GS, which would be expected as there are loci within the T2D GS which also raise fasting glucose (e.g. GCK, MTNR1B) (9) . Thus, the observation that the FPG GS was not higher in women with a 2-hour glucose ≥ 7.8 mmol/L alone was expected. However, we hypothesized that women with isolated fasting hyperglycaemia might have a genetically higher FPG, without a genetic predisposition to T2D. Despite FPG being less correlated with the T2D GS than 2-hour glycemia, the T2D GS was still associated with the fasting hyperglycemia only criteria, suggesting that these women may possess genetic risk factors for T2D independent of fasting and 2-hour glucose levels.
We observed the highest BMIs in women diagnosed with GDM by fasting hyperglycemia only or both criteria, which is consistent with previous research showing that women diagnosed with GDM by IADPSG 2010 criteria were more overweight than those diagnosed by WHO 1996 criteria (7, 20) . However, the associations with FPG GS and T2D GS are not driven by BMI, suggesting that women with fasting hyperglycemia in pregnancy are likely to have both a metabolic and genetic predisposition to T2D.
Women diagnosed with GDM with 2-hour glucose levels ≥ 7.8 mmol/L had a higher T2D GS than controls in HAPO and DIP. Since the lower FPG threshold as part of the IADPSG 2010 criteria was associated with a higher genetic risk for T2D, we considered whether the higher 2-hour glucose level may miss women who are also at a higher genetic risk for T2D. But, an association between 2-hour glucose and the T2D GS between 7.8 mmol/L and 8.5 mmol/L was not observed, whereas a higher T2D GS in women with a 2hour glucose ≥ 8.5 mmol/L was present, suggesting that the higher risk is driven by those women with a 2-hour glucose above the higher threshold of 8.5 mmol/L. Impaired glucose tolerance and elevated 2-hour glucose levels during an OGTT have been demonstrated in normal pregnancy (21) . Thus, values between 7.8 and 8.5 mmol/L may be reflective of a normal physiological response to pregnancy rather than impaired glucose tolerance. On the other hand, FPG levels decrease in pregnancy (22) , so, although a threshold of 5.1 mmol/L may not be considered abnormal outside of pregnancy, it represents hyperglycemia within pregnancy.
This work specifically examining the genetic risk of T2D in women diagnosed with GDM according to different criteria supports the results from the recent HAPO Follow-Up Study (8) which showed that women diagnosed with GDM post-hoc according to IADPSG 2010 criteria had a higher risk for T2D 10 to 14 years after pregnancy. Thus, having established that pregnant women with fasting hyperglycemia alone have a higher clinical and genetic risk for T2D compared with women without GDM, the implications for clinical care need to be considered. At present, women at risk for GDM are tested with a 2-hour OGTT, but there may be no additional value in knowing the 2-hour glucose value once it has been established that the FPG is high. The HAPO study showed a continuous association between 2-hour glucose values and adverse pregnancy outcomes (5) , but there is no evidence to suggest that both a raised FPG and raised 2-hour glucose confers any additional risk for pregnancy complications or genetic risk for T2D. In the longer-term, using the lower, IADPSG 2010 FPG threshold for identifying GDM will result in more cases diagnosed, but these women would be an important target for long-term follow-up. The Diabetes Prevention Program (DPP) (23) trial found that lifestyle intervention or metformin treatment reduced risk of progression to T2D in women with impaired glucose tolerance and a history of GDM (according to relevant criteria at time of diagnosis), but a genetic risk score for T2D did not influence treatment response (24) . It is not known whether this would be different for women specifically diagnosed by IADPSG 2010 criteria, but it is likely that these women would benefit from monitoring after pregnancy.
There are limitations of this study that are important to consider. Overall, a small number of cases of GDM were analyzed, so with greater numbers there may have been clearer differences in FPG and T2D GS between the different diagnostic groups. For example, women with both a high FPG and 2-hour glucose, which is likely to represent a greater disturbance in glycemic control, may actually have a higher T2D GS than women with isolated fasting hyperglycemia alone. Furthermore, we did not study 1-hour glucose values separately, so women with an isolated raised 1-hour glucose value (i.e. normal fasting and 2-hour glucose) meeting the diagnostic threshold for GDM according to IADPSG 2010 criteria were included in the control group. However, these women made up a very small proportion of the control group (n=43 in HAPO and n=69 in DIP) and exclusion of these women with a raised 1-hour glucose alone did not influence the observed associations (Supplemental Table 3 ). It is not known whether women with a raised 1-hour glucose in addition to a raised fasting and/or 2-hour glucose have a higher genetic risk for T2D; we did not have the power in this study to investigate this, but it may be an important area of future research.
Finally, we studied women from two different studies, where there were notable differences in clinical characteristics, even for women without GDM. This likely represents differences in the background population as a whole, and there were similar patterns amongst the different diagnostic groups. Additionally, the FPG and T2D GS were consistently higher in DIP than in HAPO. This is likely to reflect differences in SNPs used to generate the genetic scores and possibly a slighter higher genetic disposition to a raised FPG and T2D in DIP. Therefore, the results of these analyses are likely to be applicable to women of European ancestry, but further larger-scale studies, including analysis of women with diverse ancestry, will be needed to confirm the associations identified in this study.
In conclusion, women diagnosed with GDM with a FPG mmol/L during a standard OGTT also have a higher genetic risk for T2D than women with normal glucose in pregnancy, but this may not be true for women with values between 7.8 mmol/L and 8.5 mmol/L. Overall, the IADPSG 2010 criteria identify an important group of women at risk for adverse pregnancy outcomes as well as a higher risk for developing future T2D (8) . This study has confirmed that this is partly due to genetic predisposition. Knowing that these women also have a higher genetic risk for fasting hyperglycemia and T2D, genetic testing could be a novel tool to identify women at high risk for GDM at an early stage of pregnancy, helping to target screening and early intervention. 
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